Overview

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary revascularization with newer generation drug-eluting stent (DES) implantation. Furthermore, the optimal OCT-based optimal expansion criteria as well as the efficacy and safety of newer generation will be investigated.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yonsei University

Treatments:

Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

1. Age 19-85 years

2. Patients who underwent coronary revascularization with newer generation DES
implantation

Exclusion Criteria:

1. Allergy or hypersensitive to ezetimibe or statin

2. Active liver disease or persistent unexplained serum AST/ALT elevation more than 2
times the upper limit of normal range

3. History of any adverse drug reaction requiring discontinuation of statin

4. Pregnant women, women with potential childbearing, or lactating women

5. Life expectancy less than 3 years

6. Inability to follow the patient over the period of 1 year after enrollment, as
assessed by the investigator

7. Inability to understand or read the informed consent